Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FENtrepid: Fenebrutinib vs Ocrelizumab in Primary Progressive Multiple Sclerosis
NCT04544449Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Oct 2020
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 28
01
Overview
A Phase 3 trial of fenebrutinib in primary progressive multiple sclerosis (PPMS), sponsored by Roche. Started Oct 2020; status: active, not recruiting.
02
Drugs
fenebrutinib
03
Conditions
primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on NCT04544449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04544449.